

March 31, 2015

Daily Market Movers (30 Mar 2015)



[Evaluate Vantage](#)

EvaluatePharma's EventAnalyzer delivers a daily global roundup of key events driving company valuations.

Detailing the previous day's top 15 market gains and losses, aligned with significant news flow driving share prices, the EventAnalyzer keeps you in touch with the latest market moves.

Top 15 Gains (%) - ranked on change in share price

		Performance: Mon 30 Mar vs. Fri 27 Mar				
Rank	Company	Listed Currency	Share Price Change	Market Cap (US\$m)	Market Cap Change	Notes on Change
1	Auspex Pharmaceuticals	USD	+42%	3193	+937	30 Mar: Teva to acquire Auspex for around \$3.5bn or \$101 per share, a premium of 42.4% over Auspex's closing price on 27 Mar.
2	Cocrystal Pharma	USD	+24%	842	+160	
3	MediGene	EUR	+20%	201	+33	30 Mar: Shares rise on 4.5x average daily trading volume.
4	Horizon Pharma	USD	+18%	3225	+497	30 Mar: Horizon to buy Hyperion Therapeutics for \$1.1bn or \$46 per share, a 7.6% premium over Hyperion's closing price on 27 Mar.
5	Atara Biotherapeutics	USD	+17%	1045	+153	
6	GENFIT	EUR	+16%	912	+125	30 Mar: Shares rebound after plunging 44% on 26 Mar, on the failure of GFT505 in a phase II NASH trial.
7	KunWha Pharmaceutical Company	KRW	+15%	249	+32	
8	Concert Pharmaceuticals	USD	+14%	331	+41	30 Mar: Company due 1.44% of the purchase price of Auspex Pharmaceuticals as a result of a license agreement.
9	Pioneer Pharma	HKD	+14%	871	+106	
10	Marksans Pharma	INR	+11%	379	+39	
11	Puma Biotechnology	USD	+11%	7653	+758	
12	Retrophin	USD	+10%	795	+76	30 Mar: Nomura initiates coverage with a "buy" rating and price target of \$31.
13	Cempra Holdings	USD	+9%	1521	+128	
14	Oxford BioMedica	GBP	+9%	466	+38	
15	Receptos	USD	+9%	5049	+398	30 Mar: Shares rise on 2.5x average daily trading volume.

Excludes companies with a market cap. movement of less than US\$25m.

Top 15 Losses (%) - ranked on change in share price

Rank	Company	Listed Currency	Performance: Mon 30 Mar vs. Fri 27 Mar			Notes on Change
			Share Price Change	Market Cap (US\$m)	Market Cap Change	
1	Can-Fite BioPharma	ILS	-56%	26	-33	30 Mar: Company's psoriasis treatment, CF101, fails to meet primary endpoint in a phase II/III trial.
2	BioDelivery Sciences International	USD	-24%	550	-177	30 Mar: Company's Clonidine Topical Gel fails in a phase III trial in diabetic neuropathy.
3	Cellular Biomedicine Group	USD	-8%	368	-31	30 Mar: Shares fall on 3x average daily trading volume.
4	Sorrento Therapeutics	USD	-8%	411	-34	
5	Medipost	KRW	-7%	495	-37	
6	TWi Pharmaceuticals	TWD	-7%	761	-58	
7	OBI Pharma	TWD	-7%	1525	-111	
8	Medigen Biotechnology	TWD	-7%	633	-46	
9	Taiwan Liposome Company	TWD	-6%	355	-27	
10	Lotus Pharmaceutical (Taiwan)	TWD	-6%	680	-45	
11	Zhejiang Wolwo Bio-Pharmaceutical	CNY	-6%	1193	-75	
12	Center Laboratories	TWD	-4%	566	-25	
13	Fuan Pharmaceutical	CNY	-3%	987	-35	
14	PharmaEngine	TWD	-3%	843	-29	
15	Walvax Biotechnology	CNY	-3%	1853	-55	

Excludes companies with a market cap. movement of less than US\$25m.

Disclaimer:

The above analysis is based on daily share prices supplied to Evaluate Ltd. by a third party. Evaluate Ltd. accepts no responsibility or liability for the accuracy of the data presented here. Neither should any data presented here be construed as a solicitation or offer to buy or sell any securities or related financial instruments.